Quick Answer
Xenon Pharmaceuticals Inc. reported Cash And Cash Equivalents At Carrying Value of $199.16 million for the year ending 2025.
- Xenon Pharmaceuticals Inc. showed an increase of +39.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Xenon Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), Xenon Pharmaceuticals Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 1,329.9%.
- Historical annual values: Fiscal year 2025: $199.16 million | Fiscal year 2024: $142.71 million | Fiscal year 2023: $148.64 million | Fiscal year 2022: $57.24 million | Fiscal year 2021: $175.69 million | Fiscal year 2020: $45.01 million | Fiscal year 2019: $24.76 million | Fiscal year 2018: $67.75 million | Fiscal year 2017: $20.49 million | Fiscal year 2016: $17.10 million | Fiscal year 2015: $58.65 million | Fiscal year 2014: $72.03 million | Fiscal year 2013: $37.95 million | Fiscal year 2012: $60.16 million | Fiscal year 2011: $13.93 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: